The Centre For Eye Research Australia

The University of Melbourne

Pterygium

CBT-001

Cloudbreak Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

The University of Melbourne | The Centre For Eye Research Australia

Site insights

Work at this site?

Active trials

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Trial sponsors